Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

Jorine de Haan, Johannes V. van Thienen, Michael Casaer, Rebekka A. Hannivoort, Kristel van Calsteren, Minke van Tuyl, Mathilde M. van Gerwen, Anne Debeer, Frédéric Amant, Rebecca C. Painter

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.
Original languageEnglish
Pages (from-to)119-124
JournalCase Reports in Oncology
Volume11
Issue number1
DOIs
Publication statusPublished - 2018

Cite this